1. Hwang Y, Chung WS, Hong KS. Evaluation of the screening tests for the diagnosis of plasma cell neoplasm. Lab Med Online. 2012; 2:80–86.
Article
2. Jung S, Kim M, Lim J, Kim Y, Han K, Min CK, et al. Serum free light chains for diagnosis and follow-up of multiple myeloma. Korean J Lab Med. 2008; 28:169–173.
Article
3. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001; 47:673–680.
Article
4. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20:1467–1473.
Article
5. Bradwell AR, Harding SJ, Fourrier NJ, Wallis GL, Drayson MT, Carr-Smith HD, et al. Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. Clin Chem. 2009; 55:1646–1655.
Article
7. Wolff F, Debaugnies F, Rozen L, Willems D, Brohet F, Brauner J, et al. Assessment of the diagnostic performances of IgA heavy and light chain pairs in patients with IgA monoclonal gammopathy. Clin Biochem. 2013; 46:79–84.
Article
8. Bradwell A, Harding S, Fourrier N, Mathiot C, Attal M, Moreau P, et al. Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients. Leukemia. 2013; 27:202–207.
Article
9. Ludwig H, Milosavljevic D, Zojer N, Faint JM, Bradwell A, Hübl W, et al. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia. 2013; 27:213–219.
Article
10. Katzmann JA, Clark R, Kyle RA, Larson DR, Therneau TM, Melton LJ 3rd, et al. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia. 2013; 27:208–212.
Article
11. Koulieris E, Panayiotidis P, Harding SJ, Kafasi N, Maltezas D, Bartzis V, et al. Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™assay: clinical and prognostic impact in multiple myeloma. Exp Hematol Oncol. 2012; 1:9.
Article
12. Tovar N, Fernández de, Elena M, Cibeira MT, Aróstegui JI, Rosiñol L, et al. Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation. Biol Blood Marrow Transplant. 2012; 18:1076–1079.
Article
13. McPherson RA, Massey HD. Henry's clinical diagnosis and management by laboratory methods. In : McPherson RA, Pincus MR, editors. Laboratory evaluation of immunoglobulin function and humoral immunity. 21th ed. Philadelphia: WB Saunders;2007. p. 835–848.
15. Kraj M, Kruk B, Szczepiński A, Warzocha K. Comparison of immunoglobulin free light chain (FLC), heavy chain/light chain (HLC) assays and immunofixation (IFE) in assessment of remission in multiple myeloma. Acta Haematol Pol. 2012; 43:122–131.
Article